I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Efficacy and Safety of Ibrutinib Therapy in Patients with C..:
Tombak, Anıl
;
Pepedil Tanrıkulu, Funda
;
Durusoy, Salih Sertaç
...
Turkish Journal of Hematology. , 2021
Link:
https://hdl.handle.net/20.500.11776/8832
RT Journal T1
Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data ; Kronik Lenfositik Lösemili Hastalarda İbrutinib Tedavisinin Etkililiği ve Güvenilirliği: Gerçek Hayat Verilerinin Retrospektif Analizi]
UL https://suche.suub.uni-bremen.de/peid=base-ftnamikkemaluniv:oai:acikerisim.nku.edu.tr:20.500.11776_8832&Exemplar=1&LAN=DE A1 Tombak, Anıl A1 Pepedil Tanrıkulu, Funda A1 Durusoy, Salih Sertaç A1 Dinçyürek, Hüseyin Derya A1 Kaya, Emin A1 Ümit, Elif Gülsüm A1 Ferhanoğlu, Burhan A1 Akpınar, Seval A1 Turgut, Burhan PB Galenos Yayincilik YR 2021 K1 Chronic lymphocytic leukemia K1 Ibrutinib K1 Bruton's tyrosine kinase inhibitor K1 Fludarabine Plus Cyclophosphamide K1 Open-Label K1 Follow-Up K1 Cll K1 Chemoimmunotherapy K1 Rituximab K1 Trial K1 Lymphoma K1 Phase-3 JF Turkish Journal of Hematology LK http://dx.doi.org/https://hdl.handle.net/20.500.11776/8832 DO https://hdl.handle.net/20.500.11776/8832 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)